Overview

Microdosing Psychedelics to Improve Mood

Status:
Not yet recruiting

Trial end date:
2023-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this trial is to examine the safety and efficacy of small (2mg) sub hallucinogenic doses of psilocybin in people with Persistent Depressive Disorder.

Phase:

Phase 2

Details

Lead Sponsor:

Rotem Petranker

Collaborator:

Nikean Foundation

Treatments:

Psilocybin